x.com· @ · X·· 2026-04-22Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Body
Today at @AACR, we announced updated clinical data from two Phase 1/2 trials evaluating our RAS(ON) multi-selective inhibitor in patients with previously untreated metastatic pancreatic cancer.
Read more: https://t.co/agVKrMNYkJ
#AACR26 #PancreaticCancer https://t.co/5RpkrXS5Ze
Heat 24 · 19 likes · 2 replies · 3 reposts
Source: x.com · x.com